Domain Therapeutics Logo
Search on our website
Type Enter to start searching.
Pipeline

Precision Science
Transforming Lives

Delivering breakthrough GPCR-targeting therapies that bring hope to patients, especially in immuno-oncology and inflammation.
We harness the transformative power of GPCR science to address significant unmet medical needs.
By translating intricate GPCR biology into highly differentiated therapies, we challenge traditional approaches
and deliver innovative strategies with the potential to change lives.

Discover Domain

Modulating the power
of the immune system

With our deep scientific expertise in the GPCR field and our unique platform, we are unlocking the full therapeutic potential of GPCRs, including those previously considered challenging to target.

At Domain, we push the boundaries to develop breakthrough treatments for patients. Our innovative drug discovery and development approach delivers GPCR-targeting therapies that modulate the immune system, ensuring optimal clinical development and maximum benefit for patients.

Each therapy is meticulously designed to improve efficacy and impact patient outcomes thanks to its precise positioning, clinical development strategy, and its unique biological mechanisms. This strategic focus is particularly transformative for complex diseases in immuno-oncology and inflammation, two fields where GPCRs remain underexplored.

Driving precision science
in immuno-oncology & inflammation

Our robust clinical-stage pipeline reflects over two decades of proven success, validated through partnerships with leading pharmaceutical companies and investors. This track record underscores the strength of our proprietary technology and unmatched expertise.

Domain’s ability to address complex GPCR biology at every step of drug discovery and development drives clinical strategies that address significant unmet medical needs in transformative ways.

Our flagship programs, such as DT-9046, a first-in-class biased antagonist of PAR2,
and DT-7012, a best-in-class Treg depleting anti-CCR8 antibody, exemplify our innovative leadership in targeting challenging GPCRs. With highly differentiated profiles, these therapies are positioned to create significant value while establishing a strong presence in a competitive, fast-growing markets.

Our proprietary assets

Our growing portfolio of assets

  Discovery
Candidate
Preclinical
Phase I
Partner
DT-9081 - EP4 receptor antagonist
Solid Tumors +
Phase I
DT-7012 - Anti-CCR8 depleting antibody
Solid Tumors +
Preclinical
DT-9046 - Biased antagonist of PAR2
Inflammation +
Preclinical
Undisclosed GPCR targets
+
Discovery

Pressroom